A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)

Trial Profile

A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs FFP 104 (Primary)
  • Indications Biliary cirrhosis
  • Focus Adverse reactions
  • Sponsors FF Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Sep 2016 This study has been discontinued in Netherlands as per European Clinical Trials Database record.
    • 23 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top